News
Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...
Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter.
Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed ...
Amgen reported adjusted profit of $1.235 billion, down 2% from $1.265 billion a year prior, and earnings per share of $1.14 a share, up 2% from $1.12 a share a year prior.
Amgen AMGN, -0.76% said fourth-quarter net profit declined to $163 million, or 15 cents per share, from $210 million, or 19 cents per share, in the fourth quarter of 2000.
Amgen said fourth-quarter profit rose 1 percent as research spending climbed faster than sales of its anemia and cancer drugs. Net income climbed to $833 million, or 71 cents a share, from $824 ...
Biotech drug maker Amgen Inc. said Tuesday that its third-quarter profit jumped 24%, trouncing analysts' expectations, as sales of more than half a dozen of its drugs increased by double digits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback